Your browser doesn't support javascript.
loading
Precision medicine in breast cancer (Review).
Papalexis, Petros; Georgakopoulou, Vasiliki Epameinondas; Drossos, Panagiotis V; Thymara, Eirini; Nonni, Aphrodite; Lazaris, Andreas C; Zografos, George C; Spandidos, Demetrios A; Kavantzas, Nikolaos; Thomopoulou, Georgia Eleni.
Afiliación
  • Papalexis P; First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Georgakopoulou VE; Department of Biomedical Sciences, University of West Attica, 12243 Athens, Greece.
  • Drossos PV; Department of Pathophysiology, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Thymara E; Department of Biomedical Sciences, University of West Attica, 12243 Athens, Greece.
  • Nonni A; First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Lazaris AC; First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Zografos GC; First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Spandidos DA; Department of Propedeutic Surgery, Hippokration Hospital, University of Athens Medical School, 11527 Athens, Greece.
  • Kavantzas N; Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
  • Thomopoulou GE; First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Mol Clin Oncol ; 21(5): 78, 2024 Nov.
Article en En | MEDLINE | ID: mdl-39246849
ABSTRACT
Precision medicine in breast cancer is a revolutionary approach that customizes diagnosis and treatment based on individual and tumor characteristics, departing from the traditional one-size-fits-all approach. Breast cancer is diverse, with various subtypes driven by distinct genetic mutations. Understanding this diversity is crucial for tailored treatment strategies that target specific vulnerabilities in each tumor. Genetic testing, particularly for mutations in breast cancer gene (BRCA) DNA repair-associated genes, helps assess hereditary risks and influences treatment decisions. Molecular subtyping guides personalized treatments, such as hormonal therapies for receptor-positive tumors and human epidermal growth factor receptor 2 (HER2)-targeted treatments. Targeted therapies, including those for HER2-positive and hormone receptor-positive breast cancers, offer more effective and precise interventions. Immunotherapy, especially checkpoint inhibitors, shows promise, particularly in certain subtypes such as triple-negative breast cancer, with ongoing research aiming to broaden its effectiveness. Integration of big data and artificial intelligence enhances personalized treatment strategies, while liquid biopsies provide real-time insights into tumor dynamics, aiding in treatment monitoring and modification. Challenges persist, including accessibility and tumor complexity, but emerging technologies and precision prevention offer hope for improved outcomes. Ultimately, precision medicine aims to optimize treatment efficacy, minimize adverse effects and enhance the quality of life for patients with breast cancer.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Clin Oncol Año: 2024 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Mol Clin Oncol Año: 2024 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Reino Unido